LncRNAs as Regulators of Atherosclerotic Plaque Stability
Cells · 2023
DOI: 10.3390/cells12141832 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Aleksa Petkovic und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical-Hospital Centre "Dr Dragiša Mišović-Dedinje", 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, RNA, Long Noncoding, Atherosclerosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE, Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy.
Abstract (Originalsprache)
Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical-Hospital Centre "Dr Dragiša Mišović-Dedinje", 11000 Belgrade, Serbia.
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
- Intern Clinic, Clinical Ward for Cardiovascular Diseases, Clinical-Hospital Centre Zvezdara, 11000 Belgrade, Serbia.
- Department for Internal Medicine, Faculty of Dentistry, University of Belgrade, 11000 Belgrade, Serbia.
- Centre for Cardiovascular Science, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK.
ORCID-Profile: Aleksandar Davidovic, Dane Cvijanovic, Miron Sopic
Förderung
- British Heart Foundation
- HORIZON-MSCA-2021-SE-01-01—MSCA Staff Exchanges 2021 CardioSCOPE
- Ministry of Education, Science and Technological Development, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy
- Science Fund of the Republic of Serbia
- British Heart Foundation (BHF) Career Re-entry Fellowship
Zitieren
APA
Petkovic, A., Erceg, S., Munjas, J., Ninic, A., Vladimirov, S., Davidovic, A., Vukmirovic, L., Milanov, M., Cvijanovic, D., Mitic, T., & Sopic, M. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. Cells. https://doi.org/10.3390/cells12141832
Vancouver
Petkovic A, Erceg S, Munjas J, Ninic A, Vladimirov S, Davidovic A, et al. LncRNAs as Regulators of Atherosclerotic Plaque Stability. Cells. 2023. doi:10.3390/cells12141832
BibTeX
@article{Petkovic2023,
author = {Petkovic, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninic, Ana and Vladimirov, Sandra and Davidovic, Aleksandar and Vukmirovic, Luka and Milanov, Marko and Cvijanovic, Dane and Mitic, Tijana and Sopic, Miron},
title = {LncRNAs as Regulators of Atherosclerotic Plaque Stability},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12141832}
}
EUVIMED